These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34341168)

  • 1. Design of Broadly Cross-Reactive M Protein-Based Group A Streptococcal Vaccines.
    Aranha MP; Penfound TA; Salehi S; Botteaux A; Smeesters P; Dale JB; Smith JC
    J Immunol; 2021 Aug; 207(4):1138-1149. PubMed ID: 34341168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptides.
    Aranha MP; Penfound TA; Spencer JA; Agarwal R; Baudry J; Dale JB; Smith JC
    J Biol Chem; 2020 Mar; 295(12):3826-3836. PubMed ID: 32029479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
    Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
    Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a 26-valent group A streptococcal vaccine.
    Hu MC; Walls MA; Stroop SD; Reddish MA; Beall B; Dale JB
    Infect Immun; 2002 Apr; 70(4):2171-7. PubMed ID: 11895984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study.
    Pastural É; McNeil SA; MacKinnon-Cameron D; Ye L; Langley JM; Stewart R; Martin LH; Hurley GJ; Salehi S; Penfound TA; Halperin S; Dale JB
    Vaccine; 2020 Feb; 38(6):1384-1392. PubMed ID: 31843270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes.
    Spencer JA; Penfound T; Salehi S; Aranha MP; Wade LE; Agarwal R; Smith JC; Dale JB; Baudry J
    Vaccine; 2021 Mar; 39(12):1773-1779. PubMed ID: 33642159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of synthetic, M type-specific peptides as antigens in a multivalent group A streptococcal vaccine.
    Bruner M; James A; Beall B; Carlone GM; Ades E; Johnson S; Guarner J; Sampson J
    Vaccine; 2003 Jun; 21(21-22):2698-703. PubMed ID: 12798606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci.
    Dale JB; Penfound TA; Chiang EY; Walton WJ
    Vaccine; 2011 Oct; 29(46):8175-8. PubMed ID: 21920403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-guided design of a broadly cross-reactive multivalent group a streptococcal vaccine.
    Dale JB; Aranha MP; Penfound TA; Salehi S; Smith JC
    Vaccine; 2023 Sep; 41(40):5841-5847. PubMed ID: 37596198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses.
    Bronze MS; Courtney HS; Dale JB
    J Immunol; 1992 Feb; 148(3):888-93. PubMed ID: 1370521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine.
    Finn MB; Penfound TA; Salehi S; Ogega CO; Dold C; Plante O; Dale JB
    Vaccine; 2024 Sep; 42(22):126205. PubMed ID: 39141987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
    Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
    Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci.
    Brandt ER; Teh T; Relf WA; Hobb RI; Good MF
    Infect Immun; 2000 Dec; 68(12):6587-94. PubMed ID: 11083769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
    Pandey M; Mortensen R; Calcutt A; Powell J; Batzloff MR; Dietrich J; Good MF
    J Immunol; 2016 Apr; 196(8):3364-74. PubMed ID: 26969753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia.
    Pandey M; Langshaw E; Hartas J; Lam A; Batzloff MR; Good MF
    J Immunol; 2015 Jun; 194(12):5915-25. PubMed ID: 25980008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant tetravalent group A streptococcal M protein vaccine.
    Dale JB; Chiang EY; Lederer JW
    J Immunol; 1993 Aug; 151(4):2188-94. PubMed ID: 8345202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
    McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
    Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
    Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
    BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
    Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
    Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Group A streptococcus expresses a trio of surface proteins containing protective epitopes.
    Niedermeyer SE; Penfound TA; Hohn C; Li Y; Homayouni R; Zhao J; Dale JB
    Clin Vaccine Immunol; 2014 Oct; 21(10):1421-5. PubMed ID: 25080552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.